RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients

Starting soon · Phase 4

Conditions studied: CAR-T Cell Therapy, RSV Immunization, Bone Marrow Transplant - Autologous or Allogeneic

In brief

This study evaluates whether the RSV vaccine Abrysvo can produce an antibody response in patients with blood cancers who have previously received a hematopoietic stem cell transplant (HSCT) or CAR-T cell therapy. The vaccine targets the prefusion F (preF) protein of RSV, which is an important component of protective immunity against the virus. The main goal of the study is to measure the change in antibody levels against the preF protein four weeks after vaccination compared with levels before vaccination. The study will also assess whether participants develop a meaningful immune response, defined as at least a four-fold increase in RSV neutralizing antibody levels four weeks after vaccination.

Key facts

Study ID

NCT07296120

Run by

The Cooper Health System

People needed

30

Starts

2026-01-01

Expected to finish

2027-06-30

Last updated by the study team

2025-12-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older
• Diagnosis of hematological malignancy
• Treatment with HSCT or CAR-T therapy
• Must be able to give informed consent
• Must be willing to provide blood samples after HSCT or CAR-T therapy and prior to vaccination
• Must be willing to provide blood samples at four weeks and six months post-vaccination
• Must have an insurance plan that covers the cost of recieving the RSV vaccine.

You may not qualify if…

• History of a severe allergic reaction to any component of the RSV vaccine
• Use of intravenous immunoglobulin (IVIG) for hypogammaglobulinemia within the past six months

Where it is running

• Cooper University Hospital — Camden, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.